Phosphoinositide 3-kinase p110β activity: Key role in metabolism and mammary gland cancer but not development

Science Signaling

Volumn 1, Issue 36, 2008, Pages

  Ciraolo, Elisa ^a   Iezzi, Manuela ^b   Marone, Romina ^c   Marengo, Stefano ^a   Curcio, Claudia ^d   Costa, Carlotta ^a   Azzolino, Ornella ^a   Gonella, Cristiano ^a   Rubinetto, Cristina ^a   Wu, Haiyan ^e   Dastrù, Walter ^a   Martin, Erica L ^a   Silengo, Lorenzo ^a   Altruda, Fiorella ^a   Turco, Emilia ^a   Lanzetti, Letizia ^a   Musiani, Piero ^b   Rückle, Thomas ^f   Rommel, Christian ^f   Backer, Jonathan M ^e   Forni, Guido ^d   Wymann, Matthias P ^c   Hirsch, Emilio ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF TURIN   (Italy)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f MERCK SERONO S A   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 PHOSPHATIDYLINOSITOL 3 KINASE P110 SUBUNIT, MOUSE; 1-PHOSPHATIDYLINOSITOL 3-KINASE P110 SUBUNIT, MOUSE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, MOUSE; PHOSPHATIDYLINOSITOL 3 KINASE;

AGING; ANIMAL; ARTICLE; CELL CULTURE; CELL TRANSFORMATION; ENDOCYTOSIS; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL NEOPLASM; GENETICS; INSULIN RESISTANCE; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AGING; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; ENDOCYTOSIS; INSULIN RESISTANCE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, MUTANT STRAINS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 55649084906     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.1161577     Document Type: Article

References (38)

1. M. P. Wymann, R. Marone, Phosphoinositide 3-kinase in disease: Timing, location, and scaffolding. Curr. Opin. Cell Biol. 17, 141-149 (2005).
2. J. A. Engelman, J. Luo, L. C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619 (2006).
3. E. Hirsch, C. Costa, E. Ciraolo, Phosphoinositide 3-kinases as a common platform for multi-hormone signaling. J. Endocrinol. 194, 243-256 (2007).
4. L. C. Foukas, M. Claret, W. Pearce, K. Okkenhaug, S. Meek, E. Peskett, S. Sancho, A. J. Smith, D. J. Withers, B. Vanhaesebroeck, Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366-370 (2006).
5. Z. A. Knight, B. Gonzalez, M. E. Feldman, E. R. Zunder, D. D. Goldenberg, O. Williams, R. Loewith, D. Stokoe, A. Balla, B. Toth, T. Balla, W. A. Weiss, R. L. Williams, K. M. Shokat, A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125, 733-747 (2006).
6. K. Okkenhaug, A. Bilancio, G. Farjot, H. Priddle, S. Sancho, E. Peskett, W. Pearce, S. E. Meek, A. Salpekar, M. D. Waterfield, A. J. Smith, B. Vanhaesebroeck, Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297, 1031-1034 (2002).
7. S. P. Jackson, S. M. Schoenwaelder, I. Goncalves, W. S. Nesbitt, C. L. Yap, C. E. Wright, V. Kenche, K. E. Anderson, S. M. Dopheide, Y. Yuan, S. A. Sturgeon, H. Prabaharan, P. E. Thompson, G. D. Smith, P. R. Shepherd, N. Daniele, S. Kulkarni, B. Abbott, D. Saylik, C. Jones, L. Lu, S. Giuliano, S. C. Hughan, J. A. Angus, A. D. Robertson, H. H. Salem, PI 3-kinase p110beta: A new target for antithrombotic therapy. Nat. Med. 11, 507-514 (2005).
8. L. Bi, I. Okabe, D. J. Bernard, R. L. Nussbaum, Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm. Genome 13, 169-172 (2002).
9. A. G. Bader, S. Kang, L. Zhao, P. K. Vogt, Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 5, 921-929 (2005).
10. A. G. Bader, S. Kang, P. K. Vogt, Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 1475-1479 (2006).
11. S. Kang, A. G. Bader, P. K. Vogt, Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U.S.A. 102, 802-807 (2005).
12. J. J. Zhao, Z. Liu, L. Wang, E. Shin, M. F. Loda, T. M. Roberts, The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 102, 18443-18448 (2005).
13. S. Kang, A. Denley, B. Vanhaesebroeck, P. K. Vogt, Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 103, 1289-1294 (2006).
14. C. Benistant, H. Chapuis, S. Roche, A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 19, 5083-5090 (2000).
15. A. J. Robertson, S. Jackson, V. Kenche, C. Yaip, H. Parbaharan, P. Thompson (2001). International Patent Application (Patent WO 0153266 A1).
16. S. Christoforidis, M. Miaczynska, K. Ashman, M. Wilm, L. Zhao, S. C. Yip, M. D. Waterfield, J. M. Backer, M. Zerial, Phosphatidylinositol-3-OH kinases are Rab5 effectors. Nat. Cell Biol. 1, 249-252 (1999).
17. H. W. Shin, M. Hayashi, S. Christoforidis, S. Lacas-Gervais, S. Hoepfner, M. R. Wenk, J. Modregger, S. Uttenweiler-Joseph, M. Wilm, A. Nystuen, W. N. Frankel, M. Solimena, P. De Camilli, M. Zerial, An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathway. J. Cell Biol. 170, 607-618 (2005).
18. U. Maier, A. Babich, B. Nurnberg, Roles of non-catalytic subunits in gbetagamma-induced activation of class I phosphoinositide 3-kinase isoforms beta and gamma. J. Biol. Chem. 274, 29311-29317 (1999).
19. C. Murga, S. Fukuhara, J. S. Gutkind, A novel role for phosphatidylinositol 3-kinase beta in signaling from G protein-coupled receptors to Akt. J. Biol. Chem. 275, 12069-12073 (2000).
20. L. Lanzetti, A. Palamidessi, L. Areces, G. Scita, P. P. Di Fiore, Rab5 is a signalling GTPase involved in actin remodelling by receptor tyrosine kinases. Nature 429, 309-314 (2004).
21. C. T. Guy, M. A. Webster, M. Schaller, T. J. Parsons, R. D. Cardiff, W. J. Muller, Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. U.S.A. 89, 10578-10582 (1992).
22. K. Boggio, G. Nicoletti, E. Di Carlo, F. Cavallo, L. Landuzzi, C. Melani, M. Giovarelli, I. Rossi, P. Nanni, C. De Giovanni, P. Bouchard, S. Wolf, A. Modesti, P. Musiani, P. L. Lollini, M. P. Colombo, G. Forni, Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188, 589-596 (1998).
23. R. Nahta, D. Yu, M. C. Hung, G. N. Hortobagyi, F. J. Esteva, Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 3, 269-280 (2006).
24. C. Chaussade, G. W. Rewcastle, J. D. Kendall, W. A. Denny, K. Cho, L. M. Gronning, M. L. Chong, S. H. Anagnostou, S. P. Jackson, N. Daniele, P. R. Shepherd, Evidence for functional redundancy of class IA PI3K isoforms in insulin signalling. Biochem. J. 404, 449-458 (2007).
25. E. Patrucco, A. Notte, L. Barberis, G. Selvetella, A. Maffei, M. Brancaccio, S. Marengo, G. Russo, O. Azzolino, S. D. Rybalkin, L. Silengo, F. Altruda, R. Wetzker, M. P. Wymann, G. Lembo, E. Hirsch, PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118, 375-387 (2004).
26. E. Hirsch, G. Lembo, G. Montrucchio, C. Rommel, C. Costa, L. Barberis, Signaling through PI3Kgamma: A common platform for leukocyte, platelet and cardiovascular stress sensing. Thromb. Haemost. 95, 29-35 (2006).
27. S. Jia, Z. Liu, S. Zhang, P. Liu, L. Zhang, S. H. Lee, J. Zhang, S. Signoretti, M. Loda, T. M. Roberts, J. J. Zhao, Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008).
28. J. Guillermet-Guibert, K. Bjorklof, A. Salpekar, C. Gonella, F. Ramadani, A. Bilancio, S. Meek, A. J. Smith, K. Okkenhaug, B. Vanhaesebroeck, The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc. Natl. Acad. Sci. U.S.A. 105, 8292-8297 (2008).
29. S. B. Biddinger, C. R. Kahn, From mice to men: Insights into the insulin resistance syndromes. Annu. Rev. Physiol. 68, 123-158 (2006).
30. S. E. Ozanne, C. B. Jensen, K. J. Tingey, M. S. Martin-Gronert, L. Grunnet, C. Brons, H. Storgaard, A. A. Vaag, Decreased protein levels of key insulin signalling molecules in adipose tissue from young men with a low birthweight: Potential link to increased risk of diabetes? Diabetologia 49, 2993-2999 (2006).
31. L. C. Foukas, C. A. Beeton, J. Jensen, W. A. Phillips, P. R. Shepherd, Regulation of phosphoinositide 3-kinase by its intrinsic serine kinase activity in vivo. Mol. Cell Biol. 24, 966-975 (2004).
32. N. E. Hynes, H. A. Lane, ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 5, 341-354 (2005).
33. L. H. Saal, K. Holm, M. Maurer, L. Memeo, T. Su, X. Wang, J. S. Yu, P. O. Malmstrom, M. Mansukhani, J. Enoksson, H. Hibshoosh, A. Borg, R. Parsons, PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65, 2554-2559 (2005).
34. R. Carbone, S. Fre, G. Iannolo, F. Belleudi, P. Mancini, P. G. Pelicci, M. R. Torrisi, P. P. Di Fiore, eps15 and eps15R are essential components of the endocytic pathway. Cancer Res. 57, 5498-5504 (1997).
35. S. M. Brachmann, K. Ueki, J. A. Engelman, R. C. Kahn, L. C. Cantley, Phosphoinositide 3-kinase catalytic subunit deletion and regulatory subunit deletion have opposite effects on insulin sensitivity in mice. Mol. Cell Biol. 25, 1596-1607 (2005).
36. C. M. Taniguchi, T. Kondo, M. Sajan, J. Luo, R. Bronson, T. Asano, R. Farese, L. C. Cantley, C. R. Kahn, Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab. 3, 343-353 (2006).
37. A. Mora, C. Lipina, F. Tronche, C. Sutherland, D. R. Alessi, Deficiency of PDK1 in liver results in glucose intolerance, impairment of insulin-regulated gene expression and liver failure. Biochem. J. 385, 639-648 (2005).
38. E. Quaglino, S. Rolla, M. Iezzi, M. Spadaro, P. Musiani, C. De Giovanni, P. L. Lollini, S. Lanzardo, G. Forni, R. Sanges, S. Crispi, P. De Luca, R. Calogero, F. Cavallo, Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J. Clin. Invest. 113, 709-717 (2004).